The present disclosure discloses use of a miRNA 148 cluster as a marker for diagnosing and/or treating cognitive impairment-associated diseases. The present disclosure provides use of the miRNA 148 cluster in the diagnosis and treatment of cognitive impairment-associated diseases. The expression level of the miRNA 148 cluster is detected using primers for the microRNA through cognitive impairment-associated disease models, and it is found that the expression of the miRNA 148 cluster is significantly reduced during the progression of the cognitive impairment-associated diseases. The hyperphosphorylation of Tau in AD pathology is inhibited by down-regulating the PTEN and targeting p35 to improve the pathological process of AD. Therefore, the miRNA 148 cluster can be used as a novel cognitive impairment-associated disease marker for the auxiliary diagnosis and treatment of cognitive impairment-associated diseases. IM vs WT 3M vs.WT 6M vs.WT 9M vs.WT miR-54l-3p miR,-3O69-.5p miR-96-3p1 iniR-200a-3p miFr-148a-3p Eo
Use of miRNA 148 Cluster as Marker for Diagnosing and/or Treating Cognitive Impairment-Associated Diseases